These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 32647909)

  • 21. Economic Evaluation of Cladribine Tablets in Patients With High Disease Activity-Relapsing-Remitting Multiple Sclerosis in the Kingdom of Saudi Arabia.
    Bohlega S; Elboghdady A; Al-Johani A; Mahajan K; Mughari MK; Al-Saqa'aby M; Mohamed O; Alarieh R; Al Malik Y
    Value Health Reg Issues; 2021 Sep; 25():189-195. PubMed ID: 34425468
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quantifying the administration and monitoring time burden of several disease-modifying therapies for relapsing multiple sclerosis in the United Kingdom: A time and motion study.
    Rog D; Brownlee W; Carod-Artal FJ; Kalra S; Barker N; Lowndes C; Pendlebury J; Leclerc S; Amin A; Ashton L; Evans H; De Cock E
    Mult Scler Relat Disord; 2024 Feb; 82():105380. PubMed ID: 38183696
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cladribine tablets for highly active relapsing-remitting multiple sclerosis in Poland: a real-world, multi-centre, retrospective, cohort study during the COVID-19 pandemic.
    Stępień A; Pogoda-Wesołowska A; Tokarz-Kupczyk E; Słowik A; Puz P; Adamczyk-Sowa M; Kurkowska-Jastrzębska I; Kułakowska A; Chorąży M; Piasecka-Stryczyńska K; Jamróz-Wiśniewska A; Bartosik-Psujek H; Rejdak K
    Neurol Neurochir Pol; 2023; 57(4):371-378. PubMed ID: 37490356
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term management of multiple sclerosis patients treated with cladribine tablets: an expert opinion.
    Meuth SG; Bayas A; Kallmann B; Kleinschnitz C; Linker R; Rieckmann P; Mäurer M
    Expert Opin Pharmacother; 2020 Nov; 21(16):1965-1969. PubMed ID: 32658554
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study.
    Giovannoni G; Soelberg Sorensen P; Cook S; Rammohan KW; Rieckmann P; Comi G; Dangond F; Hicking C; Vermersch P
    Mult Scler; 2019 May; 25(6):819-827. PubMed ID: 29716436
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of cladribine tablets on heart rate, atrio-ventricular conduction and cardiac repolarization in patients with relapsing multiple sclerosis.
    Hermann R; Litwin JS; Friberg LE; Dangond F; Munafo A
    Br J Clin Pharmacol; 2019 Jul; 85(7):1484-1494. PubMed ID: 30883839
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Substantial and comparable suppression of disease activity following early initiation of cladribine tablets, ocrelizumab or alemtuzumab as first pharmacologic treatment for relapsing multiple sclerosis: A real world study.
    Alroughani R; Al-Hashel J; Ahmed SF
    Clin Neurol Neurosurg; 2024 May; 240():108249. PubMed ID: 38513425
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modeling the impact of patient treatment preference on health outcomes in relapsing-remitting multiple sclerosis.
    van Eijndhoven E; Brauer M; Kee R; MacEwan J; Mucha L; Wong SL; Durand A; Shafrin J
    J Med Econ; 2020 May; 23(5):474-483. PubMed ID: 31903813
    [No Abstract]   [Full Text] [Related]  

  • 29. Cost-effectiveness of cladribine tablets and dimethyl fumarate in the treatment of relapsing remitting multiple sclerosis in Spain.
    Ginestal R; Rubio-Terrés C; Morán OD; Rubio-Rodríguez D; Los Santos H; Ordoñez C; Sánchez-Magro I
    J Comp Eff Res; 2023 Feb; 12(2):e220193. PubMed ID: 36705064
    [No Abstract]   [Full Text] [Related]  

  • 30. An Innovative Approach to Modelling the Optimal Treatment Sequence for Patients with Relapsing-Remitting Multiple Sclerosis: Implementation, Validation, and Impact of the Decision-Making Approach.
    Piena MA; Kroep S; Simons C; Fenwick E; Harty GT; Wong SL; van Hout BA
    Adv Ther; 2022 Feb; 39(2):892-908. PubMed ID: 34796464
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cladribine tablets: a potential new short-course annual treatment for relapsing multiple sclerosis.
    Sipe JC
    Expert Rev Neurother; 2010 Mar; 10(3):365-75. PubMed ID: 20187859
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cladribine tablets: in relapsing-remitting multiple sclerosis.
    Muir VJ; Plosker GL
    CNS Drugs; 2011 Mar; 25(3):239-49. PubMed ID: 21323395
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical and biological predictors of Cladribine effectiveness in Multiple Sclerosis: A real-world, single Centre study considering a two-year interval from year-2 dosing.
    Manni A; Oggiano F; Palazzo C; Panetta V; Gargano CD; Mangialardi V; Guerra T; Iaffaldano A; Caputo F; Iaffaldano P; Ruggieri M; Trojano M; Paolicelli D
    J Neurol Sci; 2024 Jul; 462():123070. PubMed ID: 38850773
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Clinical Pharmacology of Cladribine Tablets for the Treatment of Relapsing Multiple Sclerosis.
    Hermann R; Karlsson MO; Novakovic AM; Terranova N; Fluck M; Munafo A
    Clin Pharmacokinet; 2019 Mar; 58(3):283-297. PubMed ID: 29987837
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An update on cladribine for relapsing-remitting multiple sclerosis.
    Holmøy T; Torkildsen Ø; Myhr KM
    Expert Opin Pharmacother; 2017 Oct; 18(15):1627-1635. PubMed ID: 28858531
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cladribine Tablets: A Review in Relapsing MS.
    Deeks ED
    CNS Drugs; 2018 Aug; 32(8):785-796. PubMed ID: 30105527
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study.
    Giovannoni G; Soelberg Sorensen P; Cook S; Rammohan K; Rieckmann P; Comi G; Dangond F; Adeniji AK; Vermersch P
    Mult Scler; 2018 Oct; 24(12):1594-1604. PubMed ID: 28870107
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of Patient-Reported Outcomes in Patients with Relapsing Multiple Sclerosis Treated with Cladribine Tablets in the CLAWIR Study: 12-Month Interim Analysis.
    Rau D; Müller B; Übler S
    Adv Ther; 2023 Dec; 40(12):5547-5556. PubMed ID: 37776477
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Development of Cladribine Tablets for the Treatment of Multiple Sclerosis: A Comprehensive Review.
    Rammohan K; Coyle PK; Sylvester E; Galazka A; Dangond F; Grosso M; Leist TP
    Drugs; 2020 Dec; 80(18):1901-1928. PubMed ID: 33247831
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Economic evaluation of cladribine tablets in high disease activity (HDA) relapsing multiple sclerosis (RMS) patients in Lebanon.
    Matni M; Yamout B; Koussa S; Khamis C; Fleifel L; Sharifi S; Mohamed O
    Mult Scler Relat Disord; 2022 Nov; 67():104169. PubMed ID: 36150262
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.